<PAGE> 1
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------------
SCHEDULE 14D-1
TENDER OFFER STATEMENT PURSUANT TO SECTION 14(D)(1)
OF THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 1)
------------------------
CORDIS CORPORATION
(Name of Subject Company)
JOHNSON & JOHNSON
JNJ ACQUISITION CORP.
(Bidders)
COMMON STOCK, PAR VALUE $1.00 PER SHARE
(INCLUDING THE ASSOCIATED RIGHTS)
(Title of Class of Securities)
21852510
(CUSIP Number of Class of Securities)
------------------------
JOSEPH S. ORBAN, ESQ.
JOHNSON & JOHNSON
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK, NEW JERSEY 08933
(908) 524-2488
(Name, Address and Telephone Number of Persons authorized to
Receive Notices and Communications on Behalf of Bidders)
------------------------
COPY TO:
ROBERT A. KINDLER, ESQ.
CRAVATH, SWAINE & MOORE
WORLDWIDE PLAZA
825 EIGHTH AVENUE
NEW YORK, NEW YORK 10019
(212) 474-1000
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
Page 1 of pages
Exhibit Index's located on Page 4
<PAGE> 2
JNJ Acquisition Corp. and Johnson & Johnson hereby amend their Tender Offer
Statement on Schedule 14D-1 (the "Statement"), originally filed on October 19,
1995, with respect to JNJ Acquisition Corp.'s offer to purchase all outstanding
shares of Common Stock, par value $1.00 per share, of Cordis Corporation, a
Florida corporation, together with any associated rights, as set forth in this
Amendment No. 1. Capitalized terms not defined herein have the meanings assigned
thereto in the Statement.
ITEM 10. ADDITIONAL INFORMATION.
On October 20, 1995, J&J issued a press release, a copy of which is
attached hereto as Exhibit (a)(9) and is incorporated herein by reference.
ITEM 11. MATERIAL TO BE FILED AS EXHIBITS.
(a)(9) Press Release, dated October 20, 1995.
2
<PAGE> 3
SIGNATURES
After due inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Dated: October 19, 1995
JOHNSON & JOHNSON
By: /s/ JAMES T. LENEHAN
------------------------------------
Name: James T. Lenehan
Title: Member, Executive Committee
JNJ ACQUISITION CORP.
By: /s/ JOSEPH S. ORBAN
------------------------------------
Name: Joseph S. Orban
Title: President
3
<PAGE> 4
INDEX TO EXHIBITS
<TABLE>
<CAPTION>
SEQUENTIALLY
EXHIBIT NUMBERED
NUMBER EXHIBIT PAGE
--------- ------------------------------------------------------------------------ ------------
<C> <C> <S> <C>
(a) (9) Press Release, dated October 20, 1995. .................................
</TABLE>
4
<PAGE> 1
EXHIBIT (A)(9)
<PAGE> 2
Exhibit (a)(9)
Johnson & Johnson
New Brunswick, NJ 08933
<TABLE>
<S> <C>
Press Contact: F. Robert Kniffin
(908) 524-3535
(Home) (609) 799-0369
Investor Contact: Annie H. Lo
(908) 524-6491
(Home) (908) 580-1258
</TABLE>
DRAFT -- NOT FOR IMMEDIATE RELEASE
JOHNSON & JOHNSON ANNOUNCES HART-SCOTT-RODINO FILING
------------------------------------------------------------
New Bruswick, N.J., October 20, 1995 -- Johnson & Johnson (NYSE:JNJ)
announced today that it has made the filing required under the Hart-Scott-Rodino
Antitrust Improvements Act, and the 15-day waiting period for its tender offer
for Cordis Corporation (NASDAQ:CORD) would expire, unless extended, at 11:59
p.m. on November 4, 1995. Johnson & Johnson also announced that it has filed
preliminary written consent materials with the Securities and Exchange
Commission. As previously stated, if Cordis does not promptly agree to a $105
per share stock-for-stock merger, Johnson & Johnson intends to solicit written
consents to remove and replace the Cordis Board in order to effect such merger.
5
